US2846437A - Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof - Google Patents
Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof Download PDFInfo
- Publication number
- US2846437A US2846437A US533890A US53389055A US2846437A US 2846437 A US2846437 A US 2846437A US 533890 A US533890 A US 533890A US 53389055 A US53389055 A US 53389055A US 2846437 A US2846437 A US 2846437A
- Authority
- US
- United States
- Prior art keywords
- phenyl
- carboxylate
- ethyl
- piperidine
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000000217 alkyl group Chemical group 0.000 title description 42
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical class OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 62
- -1 substituted-alkyl radical Chemical class 0.000 description 52
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- 239000002253 acid Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000012458 free base Substances 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 230000000202 analgesic effect Effects 0.000 description 9
- 150000005840 aryl radicals Chemical class 0.000 description 9
- 150000007942 carboxylates Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 240000008042 Zea mays Species 0.000 description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 235000005822 corn Nutrition 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 5
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229940051129 meperidine hydrochloride Drugs 0.000 description 5
- QKHMFBKXTNQCTM-UHFFFAOYSA-N norpethidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCNCC1 QKHMFBKXTNQCTM-UHFFFAOYSA-N 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229960000482 pethidine Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- NIDWUZTTXGJFNN-UHFFFAOYSA-N 3-bromopropoxybenzene Chemical compound BrCCCOC1=CC=CC=C1 NIDWUZTTXGJFNN-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- BBWMASBANDIFMV-UHFFFAOYSA-N ethyl 4-phenylpiperidine-4-carboxylate;hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C1(C(=O)OCC)CC[NH2+]CC1 BBWMASBANDIFMV-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDXIHHOPZFCEAP-UHFFFAOYSA-N 2-chloroethylsulfanylbenzene Chemical compound ClCCSC1=CC=CC=C1 QDXIHHOPZFCEAP-UHFFFAOYSA-N 0.000 description 2
- YRFGJZXFUZOMGX-UHFFFAOYSA-N 3-chloropropylsulfonylbenzene Chemical compound ClCCCS(=O)(=O)C1=CC=CC=C1 YRFGJZXFUZOMGX-UHFFFAOYSA-N 0.000 description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- AWCFAHWXLZDMFB-UHFFFAOYSA-N ethyl 1-[3-(benzenesulfonyl)propyl]-4-phenylpiperidine-4-carboxylate Chemical compound C1(=CC=CC=C1)C1(CCN(CC1)CCCS(=O)(=O)C1=CC=CC=C1)C(=O)OCC AWCFAHWXLZDMFB-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- WCNLCIJMFAJCPX-UHFFFAOYSA-N pethidine hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 WCNLCIJMFAJCPX-UHFFFAOYSA-N 0.000 description 2
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- NUJGORANFDSMOL-UHFFFAOYSA-N 2-chloroethylsulfonylbenzene Chemical compound ClCCS(=O)(=O)C1=CC=CC=C1 NUJGORANFDSMOL-UHFFFAOYSA-N 0.000 description 1
- MHCNZNYUTZTDPF-UHFFFAOYSA-N 2-ethyl-1-(3-phenoxypropyl)-4-phenylpiperidine Chemical compound C(C)C1N(CCC(C1)C1=CC=CC=C1)CCCOC1=CC=CC=C1 MHCNZNYUTZTDPF-UHFFFAOYSA-N 0.000 description 1
- ZWPSMKWPNBVWFR-UHFFFAOYSA-N 2-ethyl-1-methyl-4-phenylpiperidine Chemical compound C(C)C1N(CCC(C1)C1=CC=CC=C1)C ZWPSMKWPNBVWFR-UHFFFAOYSA-N 0.000 description 1
- IRXDRTXDRBNEJI-UHFFFAOYSA-N 2-phenoxyethyl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)OCCOC1=CC=CC=C1 IRXDRTXDRBNEJI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- LIXKPRCDXDWDTA-UHFFFAOYSA-N 3-iodopropoxybenzene Chemical compound ICCCOC1=CC=CC=C1 LIXKPRCDXDWDTA-UHFFFAOYSA-N 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- QBLISOIWPZSVIK-UHFFFAOYSA-N 4-bromobutoxybenzene Chemical compound BrCCCCOC1=CC=CC=C1 QBLISOIWPZSVIK-UHFFFAOYSA-N 0.000 description 1
- CEJDPSORWDSKOB-UHFFFAOYSA-N 4-iodobutoxybenzene Chemical compound ICCCCOC1=CC=CC=C1 CEJDPSORWDSKOB-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000088885 Chlorops Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 241001274613 Corvus frugilegus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- DZZGGKPKWGPNJA-UHFFFAOYSA-N Normeperidinicacid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CCNCC1 DZZGGKPKWGPNJA-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- BGQJJSZZCXVMOB-UHFFFAOYSA-N ethyl 1-(2-chloroethyl)-4-phenylpiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(CCCl)CC1 BGQJJSZZCXVMOB-UHFFFAOYSA-N 0.000 description 1
- UKLAKWYQAPVHQH-UHFFFAOYSA-N ethyl 1-(4-phenoxybutyl)-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCCOC1=CC=CC=C1 UKLAKWYQAPVHQH-UHFFFAOYSA-N 0.000 description 1
- DLCANSQBMBAXDJ-UHFFFAOYSA-N ethyl 1-benzyl-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CC1=CC=CC=C1 DLCANSQBMBAXDJ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- MHPBDEBKBBIHLL-UHFFFAOYSA-N hexyl 4-phenylpiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OCCCCCC)CCNCC1 MHPBDEBKBBIHLL-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KUISDPUHRPZRFF-UHFFFAOYSA-N methyl 4-phenylpiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OC)CCNCC1 KUISDPUHRPZRFF-UHFFFAOYSA-N 0.000 description 1
- XAVNWNCTXQDFLF-UHFFFAOYSA-N methyl piperidin-1-ium-4-carboxylate;chloride Chemical compound Cl.COC(=O)C1CCNCC1 XAVNWNCTXQDFLF-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- OYTXOVICQCWONU-UHFFFAOYSA-N n-(3-piperidin-1-ylpropyl)aniline Chemical compound C1CCCCN1CCCNC1=CC=CC=C1 OYTXOVICQCWONU-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- DFEUKPMFLIVTAA-UHFFFAOYSA-N phenyl piperidin-1-ium-4-carboxylate chloride Chemical compound Cl.N1CCC(C(=O)OC2=CC=CC=C2)CC1 DFEUKPMFLIVTAA-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- JAAXADBRAMYOQN-UHFFFAOYSA-N propan-2-yl 4-phenylpiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCNCC1 JAAXADBRAMYOQN-UHFFFAOYSA-N 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- JWEQRJSCTFBRSI-PCLIKHOPSA-N rboxylate Chemical compound COC(=O)C1C(N2C3=O)C4=CC=CC=C4OC1(C)N=C2S\C3=C\C(C=1)=CC=C(OC)C=1COC1=CC=CC=C1C JWEQRJSCTFBRSI-PCLIKHOPSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
Definitions
- the compounds identified as lower alkyl 4-phenyl-l-(sub-- stituted)-piperidine-4-carboxylates are those having a substituted-alkyl radical as the l-substituent.
- U. S. Patent 2,167,351 broadly shows lower alkyl 4-aryl-l-(substituted)piperidine-4-carboxylates where the l-substituent is a monovalent hydrocarbon radical. Included among the specific examples are such compounds having l-methyl and l-benzyl substituents, the latter being of value primarily as intermediates for the former.
- the l-methyl compounds are now known and accepted as effective, morphine-like central analgesics and atropinelike smooth muscle neurospasmolytics in the relief of severe pain.
- l-methyl compounds are the commercially available meperidine hydrochloride, ethyl 4-phenyl-l-methylpiperidine-4-carboxylate hydrochloride.
- the intermediate l-benzyl compounds have been found to have a decidedly lower analgesic activity compared with the l-methyl compounds.
- ethyl 4-phenyl-1- benzylpiperidine-4-carboxylate as its hydrochloride has been found to be only approximately one-fourth as effective an analgesic is meperidine hydrochloride when tested by the Bass-Vander Brook modification of the DAmour-Smith method. This decrease in activity in going from l-methyl to l-benzyl would indicate that l-phenylalkyl substituents are undesirable, and would thus lead investigators away from these compounds, and away from compounds such as those of the instant invention.
- my ethyl 4-phenyl-l- (3-phenoxypropyl)piperidine-4-carboxylate as its hydrochloride salt when measured as hereinbefore mentioned, is approximately twelve times as effective an analgesic as meperidine hydrochloride, or thus having an analgesic activity approximately forty-eight times that of the corresponding known l-benzyl compound.
- ethyl 4-phenyl-l- (S-phenoxypropyl)piperidine-4acarboxylate is only about two and one-half times as toxic [intravenous toxicity in mice when measured by a procedure similar to that described by Hoppe et al., J. Pharm. & Exp. Therap. 95,
- meperidine hydrochloride so that its therapeutic index compared with meperidine hydrochloride is approximately five and one-half.
- My compounds in free base form have the formula 0%[5 C 0 O-(lower alkyl) i- Z -At n-butyl, isobutyl, Z-butyl, n-amyl, n-hexyl, and the like.
- the monocarbocyclic aryl radical having six ringcarbon atoms is an aryl radical of the benzene series and includes the unsubstituted.
- phenyl radical and phenyl radicals substituted by substituents such as nitro, amino, (lower alkyl)amino, di-(lower alkyl)amino, (lower alkanoyl)amino, lower alkoxy, lower alkylmercapto, lower alkylsulfonyl, lower alkyl, hydroxy, halo and the like.
- the substituted-phenyl radicals have preferably from one to three substituents such as those given above; and, furthermore, these substituents can be in any of the available positions of the phenyl nucleus, and where more than one substituent, they can be the same or different and they can be in any of the various position combinations relative to each other.
- the lower alkyl, (lower alkyDamino, (lower alkanoyl)amino, lower alkoxy, lower alkylmercapto and lower alkylsulfonyl substituents, and the lower alkyl radicals of said di-(lower alkyl) amino substituent each have preferably from one to six carbon atoms which can be arranged as straight or branched chains.
- the lower alkylene radical designated above as X can have from two to six carbon atoms, and preferably has two to four carbon atoms; such preferred embodiments for X include -CH CH CH(CH )CH
- the compounds of this invention can be prepared by such as the reaction of a lower alkyl 4-phenylpiperidinea 4-carboxylate. with the appropriate aryl-Z-alkanal undercatalytic hydrogenation conditions, can be used.
- Preferred Isubgenera of my invention are the come pounds having in free base form the formula H; CQQ-(l ersl l) v on, on,
- X is an alkylene radical having from two to four carbon atoms inclusive and having its free valence bonds on different carbon atoms
- Z is O or S.
- phenoxyalkyl or phenylmercaptoal kyl esters used in the process of my invention are "3 -phenoxypropyl bromide, 2-phenylrnercaptoethyl chloride, 4-phenoxybutyl iodide, 2-phenoxypropyl sulfate, 3 -phenylmercaptopropyl rncthe anesulfonate, 2-phenoxyethyl benzenesulfonate, 2-phenylmercaptobutyl para-toluenesulfonate, and the like.
- the preferred esters are the phenoxyalkyl halides and phenylnrercaptoalkyl halides.
- the reaction is carried out by heating the lower alkyl 4-phenylpiperidine-4ecarboxylate wit the appropr a phenoxyyl ins o p y capto-alkylating agent; for-example, ethylAc-phenyl-l-(iphenoxypropyl)piperidine-kcarboxylate isobtained by heating ethyl .4-phenylpiperidine-4-carboxylate with 3- phenoxypropyl bromide; and ethyl 4-phenyl-1-( 2.-phenyl- .mercaptoethyl)piperidinertrcarboxylate is obtained by heating ethyl 4-phenylpiperidineA-carbqxylate with 2-" phenylmercaptoethyl chloride.
- the reaction can be carried out either-in the-presenceor absence of. a suitable solvent, but preferably asolvent'such as a lower alkanol is used.
- a suitable solvent but preferably asolvent'such as a lower alkanol is used.
- a preferred procedure is to conduct the reaction in, refluxing n-butanol with stirring in the presence of an alkaline agent such as sodium carbonate to neutralize the hydrogen halide formed by the reaction
- an alkaline agent such as sodium carbonate
- the preferred intermediate, ethyl .4-phenylpiperidine4-carboxylate forms an insoluble carbonate when treated with carbon dioxide, a convenient way of ascertaining whether the reaction iscomplete or notis'merely to treat the reaction mixture with carbon dioxide, the absence .of axprecipitate indicating'completencss .ofthe reaction.
- the product is isolated in free base form or in the form of'an acid addition salt. 1
- An alternative and preferred procedure forpreparing the compounds of my invention where Z is NH or N(lower alkyl) consists of introducing stepwise the 1-[(a.rylamino) alkyl] substituent onto the piperidine nucleus by reacting a lower alkyl 4-phenylpiperidine-4-carboxylate with a hydroxyalkyl halide, HO-X-halogen, to form a lower alkyl 4-phenyl l--.(hydroxyalkyl)piperidine-4-carboxylate; treating this l-hydroxyalkyl compound witha 4 i the corresponding lower alkyl .4-phenyl-l-(haloalkyl)-' pi etiiae-tarb x lat havia the o mula X-halogen and then reacting the l-haloalkyl compound with an amine having the formula Ar'NHR, where R is hydrogen or a lower alkyl radical as defined and illustrated hereinabove.
- the last step is generally carried out at a temperature between about 50 C. and 150 C., preferhalogenating agent such asIhiouyl-Chloridb, phosphorus ably on a steam bath atabout '100 C.
- preferhalogenating agent such asIhiouyl-Chloridb
- phosphorus preferably on a steam bath atabout '100 C.
- Illustrative of the preparation of these l-(arylaminoalkyl) compounds are the following preparations ethyl 4-pheny1 1- [3 (3, 4 dime thojxyphenylamino)propyllpiperidine 4- carboxylate by reacting ethyl 4TphenylpiperidineA-car:,
- My new lower alkyl 4ephenyl-l-(aryl-Z-alkyl)piperidine-4-carboxylatcs are useful either in the free base form.
- acid additionsalts are within the purview of the invention.
- the acids which can be used to prepare acid addition salts are preferably those which produce, when combined with the free base, salts whose anions are relatively innocuous to the animal organism in therapeutic doses of the salts, so that the beneficial physiological properties inherent in the free base are not vitiated by side effects ascribable'to the anions.
- other appropriate acid ,additionsalts are those derived from mineral acids such as hydrobromic acid, hydriodic acid, nitric.
- acid phosphoric acid and sulfuric acid and organic acids such as acetic acid, citric acid, tartaric acid, lactic acid,quinic acid, methanesulfonic acid, ethanesulfonic acid, and the like, giving the hydrobromide, hydriodide, nitrate, phos-- phate or acid phosphate, sulfate, or bisulfate, acetate, citrateor acid citrate, tartrate or bitartrate, lactate, qui-- nate, methanesulfonate and ethanesulfonate salts, respectively.
- Ethyl 4-phenyl-l (3-phenoxypropyl)piperidine-4-carboxylate in the form of its free base was obtained by dissolving a sample of the above-described hydrochloride in water, treating the'aqueous solution with sodium hydroxide'solution, extracting the liberated base with ether, drying the ether extract over anhydrous sodium sulfate, evaporating the ether solution slowly to dryness in vacuo, chilling to induce crystallization, and recrystallizing to constant melting point fromethanol-water.
- the above-described preparation can also be carried out using ethyl 4-phenylpiperidine-4-carboxylate in free base form (11.6 g.) and only one-halfas much sodium carbonate g.).
- this preparation is carried out using other esters such as 3-phenoxypropyl paratoluen'esulfonate or 3-phenoxypropyl iodide in place of 3-phenox'y'propyl' bromide.
- Ethyl 4-phenyl-1-[2-(4-aminophenoxy)ethyllpiperidine-4-carboxylate is obtained by reducing the corresponding 1-[2-(4-nitrophenoxy)ethyll com! pound with a reducing agent efiective to reduce'nitro groups to amino groups.
- Ethyl 4-phenyl-l-[2-(4 acetylam'inophenoxy)ethyl]piperidine-4-carboxylate is obtained by reacting the corresponding 1-[2-(4-aminophenoxy)-. ethyl] compound with acetyl chlorideor aceticanhydride.
- Ethyl 4-phenyl-l-(2-phenoxyethyl)piperidine-4-carboxy'late in free base form was prepared according to the procedure described above in Example 1(A) for the conversion of ethyl 4-phenyl-l-(B-phenoxypropyl)piperidine- 4-carboxylate hydrochloride into its free base.
- Ethyl 4-phenyl-1-(2-phenylmercaptoethyl)piperidine- 4 carboxylate in free base form is obtained by dissolving a solution of the above-describedhydrochloridein water,
- EXAMPLE 3 (A) Lower alkyl 4-phenyI-I-(arylsulfonylalkyl)piperidineJ-carboxylates The preparation ofthese compounds is illustrated by the following synthesis of ethyl 4-phenyl-l-(3-phenylsulfonylpropyl)piperidinee4-carboxylate: This compound was prepared following the procedure described in EX- a mple 1(A) using 11 g. of 3-phenylsulfonylpropyl chloride, 13.5 g. of ethyl 4-phenylpiperidine-4-carboxylate hydrochloride, 15 g. of anhydrous sodium'carbonate and 100 ml. of n-butanol. of the product, ethyl 4-phenyl-l-(3-phenylsulfonylpropyl)piperidine-4-carboxylate, M. P. 87.8-89.0 C. (corn).
- the lower alkyl 4-phenyl-l-(substituted-alkyl)piperidine-4-carboxylates of my invention can be formulated in liquid preparations, e. g., aqueous or aqueous-ethanol menstruum, or in solid form, e.g., tablet or powder.
- the tablet formulation can be prepared using conventional excipients; and the power can be compounded in capsule form.
- These preparations can be administered orally, or, in the case of the aqueous preparations, intramuscularly or intravenously.
- lela'im 1 1.
- a composition of matter selectedtrom the-group 'consistingbf acompoiind having the formula din. C'O'O GoWer'alIryI) where X is a lower alkylene radicalh avingat least two esteem atoms and-having its free'valence bonds on different carbon atoms, Z is"ameni'b'er of the group consistilig'of-(D, S;-SO,'--'SO ,'NH"ahd N (lower alkyl), Ar'is a monocarbocyclic aryl radical having six ring-carbon atoms; and its acid addition salts.
- a lower alkyl' 4-phenyl-l-(arylmercaptbaikynpiperi din 4 carboxylatehaving the formula CeHa C O (Miower alkyl) N iI-S-Ar where X is a lower alkylene radical having at least two carbon-atoms and having its free valencejbonds dif- "ferent carbon atoms, and Ar is a monocarbocy'clic' aryl radical having six ring-carbon atoms.
- the process of preparing a lower alkyl 4-pheny1-1 (arylsulfonylalkyl)piperidine-4-carboxylate having the formula can COO-(lowerallryl) li-sm-at where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, and Ar is a monocarbocyclic aryl radical having six ring-carbon. atoms, which comprises heating a lower alkyl 4-phenylpiperidine-4-carboxylate with an arylsulfonylalkyl halide.
- X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, which comprises reacting the corresponding lower alkyl 4-phenyl-1-(hydroxyalkyl)piperidine-4-carboxylate with a halogenating agent.
- a lower alkyl 4-phenyl-1-(haloalkyl)piperidine- 4-carboxylate having the formula can COO-(loweralkyll HIHI is... where X is a lower alkylene radical having at least two carbon atoms and having its free valence'bonds on different carbon atoms.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Description
United States LOWER ALKYL 4-PHENYL-1-(SUBSTITUTED- ALKYL) PIPERIDINE-l-CARBOXYLATES AND PREPARATION THEREOF Bill Elpern, Albany, N. Y., assignor to Sterling Drug Inc., New York, N. Y., a corporation of Delaware No Drawing. Application September 12, 1955 Serial No. 533,899
31 Claims. (Cl. 260-293.4)
compounds identified as lower alkyl 4-phenyl-l-(sub-- stituted)-piperidine-4-carboxylates. In particular, the compounds of this invention are those having a substituted-alkyl radical as the l-substituent.
Attempts have been made for some time to develop analgesics having high activity. The highly potent morphine has the disadvantages of causing nausea, vomiting, constipation and respiratory depression, and for these reasons has been supplanted largely by meperidine, ethyl 4-phenyl 1 methylpiperidine 4 carboxylate, especially in obstetrics where depression of respiration is highly undesirable. Because of the relatively high dose required, meperidine has to be injected in hypertonic concentrations, with a consequent risk of irritation at the site of administration. This limits the choice of concentrations which can be used and restricts undesirably the free choice of optimum dosage. This situation is advantageously modified with the compounds of my invention since they are many times more potent as analgesics than meperidine and thus can be administered in smaller volumes of solution and at higher therapeutic levels of effectiveness without making the solution hypertonic. This reduces any tendency to undesirable accompanying irritation, and improves the therapeutic usefulness of the medicament.
U. S. Patent 2,167,351 broadly shows lower alkyl 4-aryl-l-(substituted)piperidine-4-carboxylates where the l-substituent is a monovalent hydrocarbon radical. Included among the specific examples are such compounds having l-methyl and l-benzyl substituents, the latter being of value primarily as intermediates for the former. The l-methyl compounds are now known and accepted as effective, morphine-like central analgesics and atropinelike smooth muscle neurospasmolytics in the relief of severe pain. An outstanding example of these l-methyl compounds is the commercially available meperidine hydrochloride, ethyl 4-phenyl-l-methylpiperidine-4-carboxylate hydrochloride. On the other hand, the intermediate l-benzyl compounds have been found to have a decidedly lower analgesic activity compared with the l-methyl compounds. For example, ethyl 4-phenyl-1- benzylpiperidine-4-carboxylate as its hydrochloride has been found to be only approximately one-fourth as effective an analgesic is meperidine hydrochloride when tested by the Bass-Vander Brook modification of the DAmour-Smith method. This decrease in activity in going from l-methyl to l-benzyl would indicate that l-phenylalkyl substituents are undesirable, and would thus lead investigators away from these compounds, and away from compounds such as those of the instant invention.
I have now prepared certain lower alkyl 4-phenyl-l- (substituted-alkyl)piperidine-4-carboxylates and surprisingly found them to be markedly superior as analgesics atent O compared with the corresponding l-benzyl compounds of U. S. Patent 2,167,351 and, indeed, more efiective than the corresponding l-methyl compounds, even meperidine itself. For example, my ethyl 4-phenyl-l- (3-phenoxypropyl)piperidine-4-carboxylate as its hydrochloride salt, when measured as hereinbefore mentioned, is approximately twelve times as effective an analgesic as meperidine hydrochloride, or thus having an analgesic activity approximately forty-eight times that of the corresponding known l-benzyl compound. In addition to having this high analgesic activity, my compounds have a relatively low toxicity; for example, ethyl 4-phenyl-l- (S-phenoxypropyl)piperidine-4acarboxylate is only about two and one-half times as toxic [intravenous toxicity in mice when measured by a procedure similar to that described by Hoppe et al., J. Pharm. & Exp. Therap. 95,
502 (1949)] as meperidine hydrochloride, so that its therapeutic index compared with meperidine hydrochloride is approximately five and one-half.
My compounds in free base form have the formula 0%[5 C 0 O-(lower alkyl) i- Z -At n-butyl, isobutyl, Z-butyl, n-amyl, n-hexyl, and the like.
The monocarbocyclic aryl radical having six ringcarbon atoms is an aryl radical of the benzene series and includes the unsubstituted. phenyl radical and phenyl radicals substituted by substituents such as nitro, amino, (lower alkyl)amino, di-(lower alkyl)amino, (lower alkanoyl)amino, lower alkoxy, lower alkylmercapto, lower alkylsulfonyl, lower alkyl, hydroxy, halo and the like. The substituted-phenyl radicals have preferably from one to three substituents such as those given above; and, furthermore, these substituents can be in any of the available positions of the phenyl nucleus, and where more than one substituent, they can be the same or different and they can be in any of the various position combinations relative to each other. The lower alkyl, (lower alkyDamino, (lower alkanoyl)amino, lower alkoxy, lower alkylmercapto and lower alkylsulfonyl substituents, and the lower alkyl radicals of said di-(lower alkyl) amino substituent, each have preferably from one to six carbon atoms which can be arranged as straight or branched chains.
The lower alkylene radical designated above as X can have from two to six carbon atoms, and preferably has two to four carbon atoms; such preferred embodiments for X include -CH CH CH(CH )CH The compounds of this invention can be prepared by such as the reaction of a lower alkyl 4-phenylpiperidinea 4-carboxylate. with the appropriate aryl-Z-alkanal undercatalytic hydrogenation conditions, can be used.
Preferred Isubgenera of my invention are the come pounds having in free base form the formula H; CQQ-(l ersl l) v on, on,
where the lower alkyl radical has one to six carbon atoms, X is an alkylene radical having from two to four carbon atoms inclusive and having its free valence bonds on different carbon atoms, and Z is O or S. These preferred embodiments are prepared byreacting a lower alkyl 4- phenylpiperidine-4-carboxylate with a 'phenyl-Z-alkylating agent, said agent being preferably a phenoxyalkyl or phenylmercaptoalkyl ester of a strong inorganic acid or an organic sulfonic acid, said ester having the formula, C H Z-X--An, where An is an anion of a strong inorganic acid or an organic sulfonic acid. Illustrative of the phenoxyalkyl or phenylmercaptoal kyl esters used in the process of my invention are "3 -phenoxypropyl bromide, 2-phenylrnercaptoethyl chloride, 4-phenoxybutyl iodide, 2-phenoxypropyl sulfate, 3 -phenylmercaptopropyl rncthe anesulfonate, 2-phenoxyethyl benzenesulfonate, 2-phenylmercaptobutyl para-toluenesulfonate, and the like. The preferred esters are the phenoxyalkyl halides and phenylnrercaptoalkyl halides. The reaction is carried out by heating the lower alkyl 4-phenylpiperidine-4ecarboxylate wit the appropr a phenoxyyl ins o p y capto-alkylating agent; for-example, ethylAc-phenyl-l-(iphenoxypropyl)piperidine-kcarboxylate isobtained by heating ethyl .4-phenylpiperidine-4-carboxylate with 3- phenoxypropyl bromide; and ethyl 4-phenyl-1-( 2.-phenyl- .mercaptoethyl)piperidinertrcarboxylate is obtained by heating ethyl 4-phenylpiperidineA-carbqxylate with 2-" phenylmercaptoethyl chloride. The reaction can be carried out either-in the-presenceor absence of. a suitable solvent, but preferably asolvent'such as a lower alkanol is used. A preferred procedureis to conduct the reaction in, refluxing n-butanol with stirring in the presence of an alkaline agent such as sodium carbonate to neutralize the hydrogen halide formed by the reaction Since the preferred intermediate, ethyl .4-phenylpiperidine4-carboxylate, forms an insoluble carbonate when treated with carbon dioxide, a convenient way of ascertaining whether the reaction iscomplete or notis'merely to treat the reaction mixture with carbon dioxide, the absence .of axprecipitate indicating'completencss .ofthe reaction. The product is isolated in free base form or in the form of'an acid addition salt. 1
An alternative and preferred procedure forpreparing the compounds of my invention where Z is NH or N(lower alkyl) consists of introducing stepwise the 1-[(a.rylamino) alkyl] substituent onto the piperidine nucleus by reacting a lower alkyl 4-phenylpiperidine-4-carboxylate with a hydroxyalkyl halide, HO-X-halogen, to form a lower alkyl 4-phenyl l--.(hydroxyalkyl)piperidine-4-carboxylate; treating this l-hydroxyalkyl compound witha 4 i the corresponding lower alkyl .4-phenyl-l-(haloalkyl)-' pi etiiae-tarb x lat havia the o mula X-halogen and then reacting the l-haloalkyl compound with an amine having the formula Ar'NHR, where R is hydrogen or a lower alkyl radical as defined and illustrated hereinabove. The last step is generally carried out at a temperature between about 50 C. and 150 C., preferhalogenating agent such asIhiouyl-Chloridb, phosphorus ably on a steam bath atabout '100 C. Illustrative of the preparation of these l-(arylaminoalkyl) compounds are the following preparations ethyl 4-pheny1 1- [3 (3, 4 dime thojxyphenylamino)propyllpiperidine 4- carboxylate by reacting ethyl 4TphenylpiperidineA-car:,
boxylate with 3,-hydroxypropyl chloride, treating the resulting ethyl 4-phenyl-l-(3-hydroxyp QPyl)piperidiner carboxy late with thionyl chloride, and heating the ethyl 4-phenyl-1- 3- chloropropyl )piperidine-4-carb oxylate thus formed with 3,4r-dimethoxyaniline; and'sthe preparation of ethyl 4-phenyl-l-[2-(N.- ethyl N phenylamino)ethyl] piperidinea l-carboxylate by reacting ethyl 4,-phenylpiperidine-.icarboxylate with Z-hydroxyethyl chloride, reacting he r su t n hy .-phe y -(2rhy roxye hy )p p 4.-carboxyl ate with thionyl chlorideand reacting the ethyl 4.- phenyl1-(25Chl0roethyl)piperidine 4 carboxylate thus formed with N-ethylaniline. v
My new lower alkyl 4ephenyl-l-(aryl-Z-alkyl)piperidine-4-carboxylatcs are useful either in the free base form.
or in the form of acid additionsalts, and these salts are within the purview of the invention. The acids which can be used to prepare acid addition salts are preferably those which produce, when combined with the free base, salts whose anions are relatively innocuous to the animal organism in therapeutic doses of the salts, so that the beneficial physiological properties inherent in the free base are not vitiated by side effects ascribable'to the anions. In practicing my'invention, I found it convenient to employ thehydrochloride salt. However, other appropriate acid ,additionsalts are those derived from mineral acids such as hydrobromic acid, hydriodic acid, nitric. acid, phosphoric acid and sulfuric acid and organic acidssuch as acetic acid, citric acid, tartaric acid, lactic acid,quinic acid, methanesulfonic acid, ethanesulfonic acid, and the like, giving the hydrobromide, hydriodide, nitrate, phos-- phate or acid phosphate, sulfate, or bisulfate, acetate, citrateor acid citrate, tartrate or bitartrate, lactate, qui-- nate, methanesulfonate and ethanesulfonate salts, respectively.
The following examples will further illustrate the invention without, however, limiting it thereto.
EXAMPLE 1 (A) Lower alkyl 41Jhenyl-1r (aryloxyazlkyl)piperidine-4- carboxylates butanol and 20 g. of anhydrous sodium carbonate was refluxedwith stirring for twenty-four hours. The reaction mixture was allowed to cool and was filtered. The filtrate was treated with carbon dioxide (either bubbled in or'addcd as the frozen solid) in order to remove any unreacted ethyl .4-phenylpiperidineA carboxylate which forms an insoluble carbonate. After filtering ,off any anim t PI pita a th tr te w s conc n rated in i suin y eld ethy 4r hen rl-t rP W XYPmPYDP PFE crystallizations from water'yielded the product, ethyl 4- phenyl-l-(3-phenoxypropyl)piperidine=4-carboxylate hydrochloride as white needles, melting" at 179.2-l8l.7 C. (corn).
Analysis.-alcd. for CggHggNOa'HCli C, 68.39; H, 7.49; O, 11.88. Found: C, 68.42; H, 7.98; O, 12.14.
Ethyl 4-phenyl-l (3-phenoxypropyl)piperidine-4-carboxylate in the form of its free base was obtained by dissolving a sample of the above-described hydrochloride in water, treating the'aqueous solution with sodium hydroxide'solution, extracting the liberated base with ether, drying the ether extract over anhydrous sodium sulfate, evaporating the ether solution slowly to dryness in vacuo, chilling to induce crystallization, and recrystallizing to constant melting point fromethanol-water. The product, ethyl 4-phenyl-l-(3'-phenoxypropyl)piperidine-4-carboxylate, 'm'elted'at 64.8-66.2 C. (com).
The above-described preparation can also be carried out using ethyl 4-phenylpiperidine-4-carboxylate in free base form (11.6 g.) and only one-halfas much sodium carbonate g.). Alternatively, this preparation is carried out using other esters such as 3-phenoxypropyl paratoluen'esulfonate or 3-phenoxypropyl iodide in place of 3-phenox'y'propyl' bromide.
Following the above procedure but using the appropriate lower 'alkyl 4-phenylp'ip'eridine-4-carboxylate and "using the 'appropriate aryloxy-alkyl'ating agent, there 'is obtained the fbllowing compounds: methyl 4-phenyl-1- (4-plienoxybutyl)piperidine-4-carboxylate, ethyl 4-'pheny1- 1'-[2-(4-'n-'butylphenoxy) ethyllpiperidine-4'carboxylate, npropyl 4 phenyl 1 (3 phenoxypropyhpiperidine 4- carbox'ylate, ethyl 4-phenyl-l- 3-(3,4-dimethoxyphenoxy) propyl]piperidine-4-carboxylate, 'isobutyl 4-phenyl-1-(2- pl'ten'oxypropyl)piperidiue 4-carboxylate, ethyl 4-phenyll. [2 (4 ethylme'rcaptophenoxy)ethyllpiperidine 4- carboxylate, n-hexyl 4-phenyl-l-(3-phenoxypropyl)piperidine 4-ca'rboxy1ate, ethyl 4-pheny -1-[2-(4-ethylsulfonyl- 'phenoxy) ethyllpip'eridine-4-carboxylate, ethyl 4-phenyl-l- 7 (4 nitrophenoxy) ethyllpiperidine 4 carboxylate, ethyl 4 phenyl 1 [2 (4 'dimethylaminophenoxy)- ethyllpiperidine 4 carboxylate, ethyl 4 phenyl l- [2 (4 n' -butylaminophenoxy)ethyllpiperidine 4- carboxylate, ethyl 4-phenyl-1-[2-(2,4-dichlorophenoxy)- ethyllpiperidine 4 --carbox-ylate, ethyl 4 phenyl '1- i'2-- (3 hydroxyphenoxy) ethyllpiperidine 4 carboxyl ate, and the like. Ethyl 4-phenyl-1-[2-(4-aminophenoxy)ethyllpiperidine-4-carboxylate is obtained by reducing the corresponding 1-[2-(4-nitrophenoxy)ethyll com! pound with a reducing agent efiective to reduce'nitro groups to amino groups. Ethyl 4-phenyl-l-[2-(4 acetylam'inophenoxy)ethyl]piperidine-4-carboxylate is obtained by reacting the corresponding 1-[2-(4-aminophenoxy)-. ethyl] compound with acetyl chlorideor aceticanhydride.
Pharmacological evaluation of ethyl 4-phenyl l-(3- 'phenoxypropyl)piperidine-4-carboxylate hydrochloride in aqueous solution administered intraperitoneally' by the Rat Thermal Stimulus Method of Bass andVander'B'rook [1. Am. Pharm. Assoc., Sci. Ed., 41, 569-570 (1952)] has shown that this compound is approximately twelve times as active an analgesic as ethyl 4-phenyl-1-methylpiperidinel-carboxylate hydrochloride, This compound was found to have an' acute toxicity (LD in mice of 13.7:L0.7 mg. per kgfwhen administered intravenously in aqueous solution.
(B) Ethyl 4-phenyl-I-(2-phen0xyethyl)piperidine-4 I carivoxylaze The preparation 'of this' compound was carried out following the procedure described above in Example 1(A) using:13.5 gJ-of ethyl4 phenylpiperidine-4-carboxylate hydrochloride, 10g: of l -phenoxyethylbrbmide, T00 ml,
. i 6 of n-buta'nol'and 20g. ofanhydrous sodium carbonate. The product in the form 'of'its hydrochloride salt melted at 1554-1572 C. (corn) when recrystallized from water.
Analysis.-Calcd. for C H NO -HCl: C, 67.79; H,
- 7.24; O, 12.30. Found: C, 68.05; H, 7.35; O, 12.80.
I Ethyl 4-phenyl-l-(2-phenoxyethyl)piperidine-4-carboxy'late in free base form was prepared according to the procedure described above in Example 1(A) for the conversion of ethyl 4-phenyl-l-(B-phenoxypropyl)piperidine- 4-carboxylate hydrochloride into its free base. The product, ethyl 4-phenyl-1-(Z-phenoxyethyl)piperidine-4-carboxylate, melted at'4l.3-42.5 C. (corn).
Pharmacological evaluation of ethyl 4-phenyl-l-(2- phenoxyethyl)piperidine-4-carboxylate hydrochloride in aqueous solution administered intraperitoneally by the Rat Thermal Stimulus Method of Bass and Vander Brook, ibid., has shown that this compound is'approximately six times as active an analgesic as ethyl 4-ph'enyl-l-methylpiperidine-4-carboxylate hydrochloride.
(C) Ethyl 4-phenyl-1-(4-phenoxybutyl)piperidine-4- carboxylate The preparation of this compound was carried out following the procedure described above in Example 1(A) using 13.4 g. of ethyl 4-'phenylpiperidine-4-carboxylate hydrochloride, 11.5 g. of 4-phenoxybutyl bromide, 20- g. of anhydrous sodium carbonate and 100 ml. of n-butanol. The product in the form of its hydrochloride salt melted at l58.O-l5 9.6 C. (corn). A yield was obtained. AnaIysis.--Calcd. for C H NO -HCl: C, 69.00;H, 7.72; Cl, 8.48. Found: C, 68.91; H, 7.33; CI, 8.22.
Pharmacological evaluation -of ethyl 4-phenyl-l-(4- phenoxybutyl)piperidine-4-carboxylate hydrochloride in aqueous solution administered intraperitoneally by the Rat Thermal Stimulus Method of Bass and Vander Brook, ibid., has shown that this compound is approximately three times as active an analgesic as ethyl 4-phenyllmethylpiperidine-4-carboxylate.
EXAMPLE 2 (A) Lower alkyl 4-phenyl-1-(arylmercaptoalkyl)piperidine-4-ca'rboxylates The preparation of these compounds is illustrated by the following synthesis of ethyl"4-phenyl-1-(2 phenylmercaptoethyDpiperidine-4-carboxylate: A mixture of 'l3'.5 g. of ethyl 4-phenylpiperidine-4-carboxylate, 8.65'g.
of 2-phenyhnercaptoethylchloride, I00 of'n-butan'ol and 15 g. of anhydrous-sodium carbonate'was refluxed with stirring for' twenty-four hours. The reaction mixture was allowed to cool and was filtered. The filtrate was treated with carbon dioxide, allowed to stand overnight, filtered and the filtrate concentrated in vacuo to yield 'etl'iyl 4-ph'enyl-l-(2-phenylmercaptoethyl)piperi dine-4-carboxylate. This free base was dissolved in one liter of water containing 6 'cc. of concentrated 'hydrochloric acid and filtered immediately. There separated from the filtrate'white crystals'which were recrystallized twice from water to yield the product, ethyl 4-phenyl-l- '(2-phenylrnercaptoethyl)piperidine-4-c'arboxylate hydrochloride, M.-P. 172.6-174.6 C. (corn).
Analysis.-Calcd.' for C H' NO SHCI: S, 7.89; CI, 8.73. Found: S, 8.20; C], 8.83.
Ethyl 4-phenyl-1-(2-phenylmercaptoethyl)piperidine- 4 carboxylate in free base form is obtained by dissolving a solution of the above-describedhydrochloridein water,
treating the aqueous solution with sodium hydroxide solution, extracting the liberated free base with ether, drying the ether solution over anhydrous sodium sulfate, evaporating slowly the ether solution in vacuo, chilling the residual material until crystalline, then recrystallizing this material from ethanol-water. The resulting product is ethyl 4-phenyl-1-(2-phenylmercaptoethyl)piperidine-4- carboxylate.
Following the above procedure for the preparatiofbf 7. a ethyl 4-phenyl-l-(2-phenylmercaptoethyl)piperidine-lcarboxylate' but using methyl 4-phenylpiperidine-4-carboxylate, isopropyl 4-phenylpiperidine-4-carboxylate, nbutyl 4-phenylpiperidine-4-carboxylate, or n-hexyl 4- phenylpiperidine-4-carboxylate in place of ethyl 4'-phenylpiperidinet-carboxylate and using the appropriate phenylmercaptoalkyl chloride in place of phenylmercaptoethyl chloride, there is obtained methyl 4-phenyl-l-(4- phenylmercaptobutyl)piperidine-4-carboxylate, isopropyl 4 phenyl 1 (2 phenylmercaptopropyl)piperidine-4- carboxylate, n butyl 4 phenyl l (2 phenylmercaptov carbonate and 250 propyl)piperidine-4 carboxylate, or n-hexyl 4-phenyl-lv (3-phenylmercaptopropyl)piperidine-4-carboxylate, re-
spectively.
(B) Ethyl 4-phenyl-1-(3-phenylmercaptopropyl)piperidine-4-carboxylate hydrochloride This compound was prepared following the procedure described above for Example 2(A) using*l3.5 g.' of
' ethyl 4-phenylpiperidine-4-carboxylate, 9.32' g. of 3- 4-carboqrylate This compound was prepared'following the procedure described in Example 3(A) using l8.2 g. of 2-phenylsulfonylethyl chloride, 24.0 g. o ethyl 4-phenylpiperidine- 4-carboxylate;hydrochloride, 30 g. of anhydrous sodium of "n-b'utanol. the product, ethyl 4-phenyl-l-(2- obtained 20.4 g... of I 4-carboxylate, M. P.
phenylsulfonylethyl)piperidine 1030-1040 C. (com).
Anzlysis calcd. fOIC H qNO S: c, 65183; H, 6.78; 0; 15.94. Found: c, 65.95; a, 6.86; 0,1 5.70.
. EXAMPLE4' (A) Loweralkyl carbozylates The preparation of these intermediate 7 compounds is illustrated by the following synthesis .of-ethyl; 4-phenylphenylmercaptopropyl chloride, 100 ml. of n-butanol and 15 g. of anhydrous sodium carbonate. The product, ethyl 4-phenyl-l-(3-phenylmercaptopropyl)piperidine-4- carboxylate hydrochloride, melted at 126.8-128.6 C. (corr.).
Analysis.Calcd. for C H NO S.HC1: C, 65.78;'H,
methylpiperidine-4-carboxylate hydrochloride.
EXAMPLE 3 (A) Lower alkyl 4-phenyI-I-(arylsulfonylalkyl)piperidineJ-carboxylates The preparation ofthese compounds is illustrated by the following synthesis of ethyl 4-phenyl-l-(3-phenylsulfonylpropyl)piperidinee4-carboxylate: This compound was prepared following the procedure described in EX- a mple 1(A) using 11 g. of 3-phenylsulfonylpropyl chloride, 13.5 g. of ethyl 4-phenylpiperidine-4-carboxylate hydrochloride, 15 g. of anhydrous sodium'carbonate and 100 ml. of n-butanol. of the product, ethyl 4-phenyl-l-(3-phenylsulfonylpropyl)piperidine-4-carboxylate, M. P. 87.8-89.0 C. (corn).
Analysis.-Calcd. for C H N0 Sr C, 66.48; H, 7.03; 05, 15.41. Found: C, 66.71; 66.45; H, 7,05, 6.85; O, 1 .50. 1
When ethyl 4-phenyl-l-(3-phenylsulfonylpropyl)piperidine-4-carboxylate is treated with hydrogen chloride, its hydrochloride is formed.
Following, the above procedure finylpropyl chloride in place of 3-phenylsulfonylpropyl chloride,- the product obtained is ethyl 4-phenyl-l-(3- phenylsulfinylprcpyl)piperidine-4-carboxylate. 7
Following the above procedure but using the appropriate lower alkyl 4-phenylpiperidine-4-carboxylate 'in place of ethyl 4-phenylpiperidine-4-carboxylate and using the appropriate arylsulfonylallrylchloride, there is oh- -tained the following respective compounds: methyl 4- phenyl 1 (4 phenylsulfonylbutyl)piperidine 4 carboxylate, ethyl 4-phenyl-l-[2- (4-n-butoxyphenylsulfonyl)- ethyl] piperidine-4-carboxylate, ethyl 4-pheny1- 1- 3- (4- nitrophenylsulfonyl propyl] piperidine-4-carboxylate, and the like.
There was thus obtained 7.4 g.
but using 3-phenylsul-.
' about forty-five "minutes 7 I heated slightly on a steam :bath
l-(2-chloroethyl)piperidine-4-carbo latezTo a solution containing 556g. of ethyl4-phenyl 1-(2-hydroxyethyl)- -piperidine-4-carboxylate and a drop-of pyridine in 400 ml. of benzene ,wasfadded'dropwise-over a period of 2.95 ig. o f thionyl chloride. The reaction mixture was at the start of the addition of the thionyl chloride and then heated on a steam 'bath for one and oneehalf hours 'after all of the thionyl chlorides had'bee'n added. The
reaction mixture was allowed to cool andithe white precipitate that had separated was collected and recrystallized once from absolute ethanol and once from 180- propanol, yielding'about 4.7 "g. .of phenyl-l-(Z-chloroethyl) piperidine-4 carboxylate; as: its hydrochloride, M. P. 218.29. C. (corn) ;-(with decomposition). i e
6.98; CI, 10.69. Found:
Following the "abgiye procedure but using appropriate lower alkyl 4,-fim 1-1-(hy o n w mq4-i.
f' the appropriate"; halogenatmg the following methyl 4pheny1'-l-(4 chlorobutyl)piperidine steaiiboxylate, ethyl; r
4' phenyl l (3 1 chlorop'rop'yhpiperidine -'-4 can; v f-' carboxylate, isobutyl 4-phenyl-'l(2-chloropropyl)piperidine-4-carboxylat e, n-h exyl 4-phenyl-l-(3-vchloropropybcarboxylate and using agent, there is obtained boxylate; ethyl 4-phenyl-1-(Z bromoethylJpi piperidine-4-carboxylate, and the like.
(B) Lower alkyl 4-ph y (drylaininoalhbp 1 I 4-earboxylates .1
The preparation of these compounds is illustrated by the following synthesis ofv v aminoethyl)piperidine-4-carboxylate: A mixture contaming 5.58 g. of aniline, 4.0 g. of anhydrous sodium carbonate and 25 ml. ofwater was heated on a steam bath at 90 .C. To this heated solution was added dropwise with stirring over a period of one and one-half hours 5.0
g. of ethyl 4-phenyl-l-(2-chloroethyl)piperidine-4-carboxylate hydrochloridejdissolved in mlof water.
Heating of the'reaction mixture was continued on a steam bath' for an additional organic was concernwas added to the 'organiclayer. washed. with saturated chloride solution,
. trated in vacuoanddistilled in anoil bath at 98"C.;at about 40 mm. pressure to remove theunreacted-sniline- The residue was dissolved in. am and hy ros nehlaiae -was bubbledinto this solution. The. precipitstelthat from absolute'sethanol.
separated was recrys d once I yielding the pr d ethyl carboxylate as its dihydrochloride, M. P.l94.2" C.
Analysis-Calcd. for C H N;O .2l-ICl:'C; 62.12; H, 7.11 O, 7.53. Found: C, 62.42; H, 7.06;,O,"7.50.
Ethyl 4 phenyl 1 (B)...'Ethyl .{fjrhehyl-I (Z-phenylsulfonylethyl)piperidine- There was thus s awns-(banal ty! ipirid m4- three hours. The reaction mixture was allowed to cool, was filtered, and v p yhm mp flh I dine i-carboxylate in the form of its free baseis obtained by-dissolving a sample'of 'the' above-described dihydrochloride in' water, treating the aqueous solution with sodium'hydroxide solution, extracting the liberated base I with'benzene; drying the benzene extract overanhydrous sodium sulfate and evaporating the benzene solution slowly to dryness in vacuo.
Other lower alkyl 4-phenyl-l-(atylaminoalkyDpiperi- -dine-4-'c'arboxylates that are obtained following the fore-.
going procedure using 'theappropriate lower alkyl 4- -i311ei'lyl-l-(ha l'oalkyl)piperidine-4-carboxylate and the appropriate arylamine are: methyl 4-phenyl-l-[4-(3,4-diethoxyphenylaniino) butyl] piperidine-4-carboxylate, ethyl "4' -"phenyl 1 (3 phenylaminopropyl)piperidine 4- "times more active as an analgesic than ethyl 4-phenyl-1- methylpiperidine-4-carboxylate hydrochloride.
The lower alkyl 4-phenyl-l-(substituted-alkyl)piperidine-4-carboxylates of my invention can be formulated in liquid preparations, e. g., aqueous or aqueous-ethanol menstruum, or in solid form, e.g., tablet or powder. The tablet formulation can be prepared using conventional excipients; and the power can be compounded in capsule form. These preparations can be administered orally, or, in the case of the aqueous preparations, intramuscularly or intravenously.
lela'im: 1 1. A composition of matter selectedtrom the-group 'consistingbf acompoiind having the formula din. C'O'O GoWer'alIryI) where X is a lower alkylene radicalh avingat least two esteem atoms and-having its free'valence bonds on different carbon atoms, Z is"ameni'b'er of the group consistilig'of-(D, S;-SO,'--'SO ,'NH"ahd N (lower alkyl), Ar'is a monocarbocyclic aryl radical having six ring-carbon atoms; and its acid addition salts.
2. Albwer' alkyl l-phenyl:l-(aryloxyallkyllpiperidine- 4-carboxylate having the formula where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, and Ar is a monocarbocyclic aryl radical having six ring-carbon atoms.
3. An acid addition salt of the compound of claim 2.
10 '4; A lower alkyl' 4-phenyl-l-(arylmercaptbaikynpiperi din 4=carboxylatehaving the formula CeHa C O (Miower alkyl) N iI-S-Ar where X is a lower alkylene radical having at least two carbon-atoms and having its free valencejbonds dif- "ferent carbon atoms, and Ar is a monocarbocy'clic' aryl radical having six ring-carbon atoms. H I
5. An acid addition salt of the compound of 4. 6. A lower alkyl 4-phenyl-l-(arylsulfonylalkyl)pipetidine-4-carboxylate having the formula CGHB COO-(lower alkyl) where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, and AI is a monocarbocylic aryl radicalhaving six ring-carbon atoms.
7.1An-acid addition salt of the compoundoi'claimj6. '8. A lower alkyl 4-phenyl-l-(arylaminoalkynpiperi- 0 C61 CHa N )LNH-Ar where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, and Ar is a monocarbocyclic aryl radical having six ring-carbon atoms.
9. An acid addition salt of the compound of claim 8. lOf-Ethyl 4 phenyl-1-( 3-phenoxypropyl)piperidine 4- carboxyl ate.
-11.*-E't'hyl 4 phenyl-l-(3-phenoxypropyllplperidine-4- ca rboxylate hydrochloride. 7 V U 12. 'Ethyl 4 phenyl 1-(2-phenox'yethyl)piperidine-'4- carboxylate hydrochloride. U
' l3.-Ethyl 4-phenyl-l-(Z-phenylarnindetliyDpipetldine- 4 'carboxyla te. I p
14." Ethyl t-phenyl l-(Z-phnylaininbethybbiperidine- 4-carboxylate dihydrochloride. v H v I, V
' 15. The process 5 of" preparinga'c'ompotind having the formula CeHs COO-(lower alkyl) where X is a lower alkylene' radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, Z is a member of the group consisting of 0, S, SO, S0 NH and N(lower alkyl) and Ar is a monocarbocyclic aryl radical having six ring-carbon atoms, which comprises reacting a lower alkyl 4-pheny1- piperidine-4-carboxylate with an aryl-Z-alkyl ester of an acid selected from the group consisting of a strong inorganic acid and an organic sulfonic acid.
16. The process of preparing a lower alkyl 4-phenyl-1- (aryloxyalkynpiperidine r 4 carboxylate having the formula N vi-S-Al' \C Ha Ha I where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms,.and Ar isa monocarbocyclic and radical having six ring-carbon atoms, which comprises heating .a lower alkyl 4-phenylpiperidine-4-carboxylate' with an arylmercaptoalkyl halide.
18. The process of preparing a lower alkyl 4-pheny1-1 (arylsulfonylalkyl)piperidine-4-carboxylate having the formula can COO-(lowerallryl) li-sm-at where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, and Ar is a monocarbocyclic aryl radical having six ring-carbon. atoms, which comprises heating a lower alkyl 4-phenylpiperidine-4-carboxylate with an arylsulfonylalkyl halide.
19.'The process of preparing ethyl 4-phenyl-1-(3- phenoxypropyl)piperidine-4-carboxylate which comprises heating ethyl 4-phenylpiperidine-4-carboxylate with 3- phenoxypropyl bromide.
.20. The process of preparing a lower alkyl4-phenyl- 1-(arylaminoalkyl)piperidine-4'carboxylate having the formula o .m COO-(loweralkyl) C CHI where'X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on differ'ent carbon, atoms, R is selected from "the'group, consisting of hydrogen and aloweralkyl radicaland Ar is a monocarbocyclic aryl radical having ring-carbon atoms,' which comprises heating a lower alkyl t -phenyl- 1w(haloaIkyDpiperidine-4-carboxylate with an amine havv 'ing .the formula a 21. The process of preparing ethyl ,4-phenyl-1-(2- phenylaminoethyl)piperidineQl-carboxylate which comprises heating ethyl 4-phenyl-l-(2-chloroethyl) piperidine- 4-carboxylate with aniline. p V 22. The process of preparing a lower alkyl 4-phenyl- 1-(haloalkyl)piperidine-4-carboxylate having the formula can COO-(loweralkyl) /C\ cm on,
where X is a lower alkylene radical having at least two carbon atoms and having its free valence bonds on different carbon atoms, which comprises reacting the corresponding lower alkyl 4-phenyl-1-(hydroxyalkyl)piperidine-4-carboxylate with a halogenating agent.-
23. A lower alkyl 4-phenyl-1-(haloalkyl)piperidine- 4-carboxylate having the formula can COO-(loweralkyll HIHI is... where X is a lower alkylene radical having at least two carbon atoms and having its free valence'bonds on different carbon atoms.
24. Ethyl 4 phenyl carboxylate.
1-(2-phenoxyethyl)piperidine-4- 25. Ethyl 4-phenyl-1-(3-phenylmercaptopropyl)piper- I idine 4-carboxylate.
26. Ethyl 4phenyl-1-(3-phenylmercaptopropyl)piperidine-4-carboxylate hydrochloride.
27. Ethyl 4 phenyl 1-(2-phenylmercaptoethyl)piperidine-4-carboxylate.
28. Ethyl 4 phenyl l-(2-phenylmercaptoethyl)piperidine-4-carboxylate hydrochloride.
29. Ethyl 4 pheny1.- 1(3-phenylsulfonylpropyl)piper-.
idine-4-carboxylate.
30. Ethyl 4 phenyl 1(3-phenylsu1fonylpropyl)piperidine-4-carboxylate hydrochloride. 7
31. Ethyl 4 phenyl 1-(3-phenylaminopropyl)piperidine-' l carbpxylate.
References Cited in the file of this patent Thorp: Journal of the Chemical Society of London for 1948, pp. 559-561, May 1948.
Schaumann: Archives of Experimental Pathology and Pharmacology, vol. 196, pp. 109-136, 1940.
Claims (1)
1. A COMPOSITION OF MATTER SELECTED FROM THE GROUP CONSISTING OF A COMPOUND HAVING THE FORMULA
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US533890A US2846437A (en) | 1955-09-12 | 1955-09-12 | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US533890A US2846437A (en) | 1955-09-12 | 1955-09-12 | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2846437A true US2846437A (en) | 1958-08-05 |
Family
ID=24127852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US533890A Expired - Lifetime US2846437A (en) | 1955-09-12 | 1955-09-12 | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2846437A (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2882276A (en) * | 1959-04-14 | Certain esters of amino alcohols | ||
| US2904550A (en) * | 1958-01-17 | 1959-09-15 | Lilly Co Eli | 4-phenylpiperidines and their preparation |
| US2955114A (en) * | 1958-03-12 | 1960-10-04 | Lakeside Lab Inc | Nor-piperidyl glycolate esters |
| US2978454A (en) * | 1955-09-12 | 1961-04-04 | Sterling Drug Inc | Lower alkyl-4-phenyl-1-[(diloweralkoxy phenyl)-aliphatic] piperidine-4-carboxylates |
| US3004976A (en) * | 1961-10-17 | Aromatic carboxylic acid esters of | ||
| US3014912A (en) * | 1957-03-12 | 1961-12-26 | British Drug Houses Ltd | Piperidine derivatives and method for preparing same |
| US3024241A (en) * | 1955-11-28 | 1962-03-06 | J F Macfarlan & Company Ltd | Nu-ether-alkylene norpethidines |
| US3093652A (en) * | 1958-10-23 | 1963-06-11 | Sterling Drug Inc | Alkyl 1-(2-aryl-2-oxoalkyl)-4-phenylpiperidine-4-carboxylates and their preparation |
| US3097209A (en) * | 1960-03-14 | 1963-07-09 | Res Lab Dr C Janssen N V | 1-aroyalkyl-4-arylpiperidine-carboxamides |
| US3131122A (en) * | 1961-04-14 | 1964-04-28 | Boehringer Sohn Ingelheim | Method of producing analgesia with n-substituted-4-phenyl-4-carbalkoxypiperidines |
| US3185702A (en) * | 1959-03-16 | 1965-05-25 | Lunsford Carl Dalton | Basic esters of 3-aryl-3-pyrrolidinols |
| US3217009A (en) * | 1959-12-18 | 1965-11-09 | Sterling Drug Inc | 1-(3-oximino-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
| US3252994A (en) * | 1959-02-12 | 1966-05-24 | Mead Johnson & Co | 1, 2-dimethyl-3-benzyl-3-propionoxy-pyrrolidine |
| US3256297A (en) * | 1958-04-02 | 1966-06-14 | Parke Davis & Co | 1, 2-dimethyl and 1, 2, 2 trimethyl-3-phenyl-3-propionyloxy pyrrolidines |
| US3275641A (en) * | 1961-02-27 | 1966-09-27 | Sterling Drug Inc | 4-acyloxy-4-aryl-1-(arylaminoalkyl) piperidines and their preparation |
| US3290317A (en) * | 1960-03-07 | 1966-12-06 | Sterling Drug Inc | 1-(nu-aryl-nu-alkanoylaminoalkyl)-4-aryl-4-piperidinols and their esters |
| US3294804A (en) * | 1961-01-27 | 1966-12-27 | Sterling Drug Inc | 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
| US3344145A (en) * | 1963-10-21 | 1967-09-26 | Geschickter Fund Med Res | N-substituted phenoxyalkyl or phenylthioalkyl-mono azaspiroalkanes |
| US3960873A (en) * | 1970-05-20 | 1976-06-01 | Sumitomo Chemical Co., Ltd. | 1-Phenylthiopropyl-4-hydroxy-4-phenyl piperidines |
| US4246267A (en) * | 1976-04-29 | 1981-01-20 | Science Union Et Cie | Aminopiperidines, their production and the pharmaceutical compositions incorporating them |
-
1955
- 1955-09-12 US US533890A patent/US2846437A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3004976A (en) * | 1961-10-17 | Aromatic carboxylic acid esters of | ||
| US2882276A (en) * | 1959-04-14 | Certain esters of amino alcohols | ||
| US2978454A (en) * | 1955-09-12 | 1961-04-04 | Sterling Drug Inc | Lower alkyl-4-phenyl-1-[(diloweralkoxy phenyl)-aliphatic] piperidine-4-carboxylates |
| US3024241A (en) * | 1955-11-28 | 1962-03-06 | J F Macfarlan & Company Ltd | Nu-ether-alkylene norpethidines |
| US3025301A (en) * | 1955-11-28 | 1962-03-13 | J F Macfarlan & Company Ltd | Ethyl-4-phenyl-nu-ether alkylene-4-piperidine carboxylates |
| US3014912A (en) * | 1957-03-12 | 1961-12-26 | British Drug Houses Ltd | Piperidine derivatives and method for preparing same |
| US2904550A (en) * | 1958-01-17 | 1959-09-15 | Lilly Co Eli | 4-phenylpiperidines and their preparation |
| US2955114A (en) * | 1958-03-12 | 1960-10-04 | Lakeside Lab Inc | Nor-piperidyl glycolate esters |
| US3256297A (en) * | 1958-04-02 | 1966-06-14 | Parke Davis & Co | 1, 2-dimethyl and 1, 2, 2 trimethyl-3-phenyl-3-propionyloxy pyrrolidines |
| US3093652A (en) * | 1958-10-23 | 1963-06-11 | Sterling Drug Inc | Alkyl 1-(2-aryl-2-oxoalkyl)-4-phenylpiperidine-4-carboxylates and their preparation |
| US3252994A (en) * | 1959-02-12 | 1966-05-24 | Mead Johnson & Co | 1, 2-dimethyl-3-benzyl-3-propionoxy-pyrrolidine |
| US3185702A (en) * | 1959-03-16 | 1965-05-25 | Lunsford Carl Dalton | Basic esters of 3-aryl-3-pyrrolidinols |
| US3217009A (en) * | 1959-12-18 | 1965-11-09 | Sterling Drug Inc | 1-(3-oximino-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
| US3290317A (en) * | 1960-03-07 | 1966-12-06 | Sterling Drug Inc | 1-(nu-aryl-nu-alkanoylaminoalkyl)-4-aryl-4-piperidinols and their esters |
| US3097209A (en) * | 1960-03-14 | 1963-07-09 | Res Lab Dr C Janssen N V | 1-aroyalkyl-4-arylpiperidine-carboxamides |
| US3294804A (en) * | 1961-01-27 | 1966-12-27 | Sterling Drug Inc | 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
| US3275641A (en) * | 1961-02-27 | 1966-09-27 | Sterling Drug Inc | 4-acyloxy-4-aryl-1-(arylaminoalkyl) piperidines and their preparation |
| US3131122A (en) * | 1961-04-14 | 1964-04-28 | Boehringer Sohn Ingelheim | Method of producing analgesia with n-substituted-4-phenyl-4-carbalkoxypiperidines |
| US3344145A (en) * | 1963-10-21 | 1967-09-26 | Geschickter Fund Med Res | N-substituted phenoxyalkyl or phenylthioalkyl-mono azaspiroalkanes |
| US3960873A (en) * | 1970-05-20 | 1976-06-01 | Sumitomo Chemical Co., Ltd. | 1-Phenylthiopropyl-4-hydroxy-4-phenyl piperidines |
| US4246267A (en) * | 1976-04-29 | 1981-01-20 | Science Union Et Cie | Aminopiperidines, their production and the pharmaceutical compositions incorporating them |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2846437A (en) | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof | |
| AP279A (en) | 4 substituted piperidine derivatives, processes for their preparation pharmaceutical compositions containing them and their use in therapy. | |
| Turner et al. | Studies on imidazole compounds. I. 4-Methylimidazole and related compounds | |
| DE2513916A1 (en) | SUBSTITUTED BENZAMIDES | |
| DE3779825T2 (en) | DERIVATIVES OF BENZHYDRYLOXYAETHYLPIPERAZINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| EP0000220B1 (en) | Dihydrouracils, process for their preparation and pharmaceuticals containing them | |
| DE2311570A1 (en) | 4-AMINOCHINOLINES, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| US2824875A (en) | Certificate of correction | |
| US3117139A (en) | 4-aryl-1-carbamylalkyl-piperidines | |
| DE3445339A1 (en) | 3,3-DISUBSTITUTED 1- (PHENYLAMINO) GUANIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| DE2719211B2 (en) | 1 - (2-Phenylamino-ethyI) -4- <N-phenyl-N-propionylamino) -piperidines, process for their preparation and pharmaceuticals containing them | |
| US4324791A (en) | Heterocyclic antidiarrheal compositions & methods of use | |
| DE2258036A1 (en) | PROCESS FOR THE MANUFACTURING OF BENZO SQUARE BRACKETS ON SQUARE BRACKETS TO THIOPHEN DERIVATIVES | |
| DE69119282T2 (en) | Aminobenzene compounds, manufacture and use | |
| DE69621712T2 (en) | Arylpiperidine and arylpiperazine derivatives and medicinal products containing them | |
| US2978454A (en) | Lower alkyl-4-phenyl-1-[(diloweralkoxy phenyl)-aliphatic] piperidine-4-carboxylates | |
| US2957873A (en) | Aralkylhydrazinium salts | |
| US3290317A (en) | 1-(nu-aryl-nu-alkanoylaminoalkyl)-4-aryl-4-piperidinols and their esters | |
| US2914533A (en) | Tertiary-aminoalkyl n-(pyridyl)carbamates and their preparation | |
| US2914532A (en) | Lower alkyl 4-phenyl-1-(3-phenylpropyl) piperidine-4-carboxylates and their preparation | |
| US2485662A (en) | Alpha-(aminoalkyl)-stilbenes | |
| LEE et al. | Piperidine derivatives. Part 1. Lobelan and related compounds | |
| DE1620746A1 (en) | Process for the preparation of phenothiazine derivatives | |
| US2650230A (en) | Xanthene-9-carboxylic acid esters of nuclearly alkylated 4-piperidinols and salts thereof | |
| US3147268A (en) | 4-amino derivatives of methylpiperidines |